Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combination nicotine replacement therapy (NRT) refers to the concurrent use of two different forms of medically approved nicotine delivery products to aid in smoking cessation. The most common regimen involves a long-acting transdermal nicotine patch, which provides a steady baseline level of nicotine throughout the day, combined with a faster-acting form such as gum, lozenge, mouth spray, inhalator (inhaler), or nasal spray. This approach is more effective than single-form NRT for helping smokers quit and is recommended for individuals who smoke more than 10 cigarettes per day. The mechanism of action involves replacing some or all of the nicotine previously obtained from tobacco with pharmaceutical-grade nicotine delivered through non-tobacco routes. This reduces withdrawal symptoms and cravings by maintaining plasma nicotine levels while avoiding exposure to harmful combustion products found in tobacco smoke[2][3][4][5]. Combination NRT has demonstrated quit rates comparable to varenicline and is considered one of the most effective pharmacotherapies for smoking cessation[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on combination nicotine replacement therapy.